On Sept. 14, 2009, the Innovative Medicines Initiative (IMI), a public–private partnership between the European Commission and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA), announced (PDF) the topics of research of its second call for proposals. IMI was launched in 2007 to “support more efficient discovery and development of better medicines for patients by removing research bottlenecks in the current drug development process,” according to an IMI release.

The IMI budget for 2008–2017 is €2 billion ($2.9 billion), with half coming from the European Community and half from industry. In April 2008, IMI received 134 proposals, 15 of which were selected to receive €246 million (approximately $359 million). The funding available for the second proposal call is €156.3 million ($227.9 million), with €76.8 million ($112 million) to be provided by the European Commission and €79.5 million ($116 million) to be provided by EFPIA member companies.

No related posts.